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Among 77 patients with endogenous hyperinsulinism seen 
in 2 medical centers, diffuse islet cell disease accounted for 
17 (22%) patients. Since diffuse islet cell disease poses spe- 
cial problems in management, its prevalence is empha- 
sized in this report. 
Among these patients with diffuse islet cell disease, there 
were 11 patients with adenomatosis, 4 with nesidioblas- 
tosis, and 2 with islet cell hyperplasia. Six of the 77 pa- 
tients were found in multiple endocrine neoplasia, type I 
kindreds; diffuse islet cell disease was documented in 4 of 
these patients. 
We outline principles of management in patients with 
diffuse islet cell disease. Frozen section microscopy failed 
to identify nesidioblastosis or islet cell hyperplasia. 
A continuing problem for surgeons operating on pa- 
tients with endogenous hyperinsulinism is what to 
do when no diseased tissue is found at surgery af- 
ter a preliminary exploration of the pancreas. Soli- 
tary beta islet cell adenomas can be overlooked 
when not palpable; identification of diffuse islet cell 
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disease poses many problems. We recognize 3 ma- 
jor diffuse islet cell disorders associated with 
hyperinsulinism: beta islet cell adenomatosis, 
which can often be recognized by the operating sur- 
geon; nesidioblastosis, and pancreatic beta cell 
hyperplasia, both of which defy operative recog- 
nition. In addition, multiple macroadenomas may 
or may not co-exist with microadenomatosis or 
hyperplasia in certain patients with hyperinsulin- 
ism. Multifocal islet cell disorders are particularly 
frequent in patients with multiple endocrine 
neoplasia, type I (MEN I). Other than to recognize 
its occurrence, we do not include in this review of 
diffuse islet cell disorders an analysis of sporadic 
beta islet cell carcinoma. In many patients, the re- 
sults of preoperative transhepatic venous catheteri- 
zation (THVC) should draw attention to the pos- 
sible presence of diffuse islet cell disease. 
Case Material  
Seventy-seven patients with hyperinsulinism were 
cared for, 69 at the University of Michigan Medi- 
cal Center since 1960 and 8 at The Milton S. Her- 
shey Medical Center of The Pennsylvania State 
University since 1973. Infants and young children 
under the age of 9 years are not included in this re- 
port. 
Solitary Islet Cell Adenoma 
While not the major focus of this report, solitary 
hyperfunctioning islet cell adenoma was the most 
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Table 1. Endogenous hyperinsulinism. 
U of M" 
Without With 
MEN MEN I MSHMC C Total 
All patients 63 6 8 77 
Solitary 
adenoma 51 1 4 56 
Adenomatosis 5 b 4 2 11 
Nesidioblas- 
tosis 3 0 1 4 
Hyperplasia 1 0 1 2 
Carcinoma 
Sporadic 3 0 0 3 
MEN I 0 1 0 1 
~University of Michigan Medical Center. 
bOne patient with macroadenomas only, 1 patient with 
macroadenomas + microadenomatosis, 3 patients with 
microadenomas + hyperplasia. 
'Milton S. Hershey Medical Center, Pennsylvania 
State University College of Medicine. 
frequent  lesion seen--56 (73%) of the 77 patients 
(Table 1). In 1 patient, the adenoma was not found 
in a blind distal 85% pancreatic resection. For  16 
years her hyperinsulinism has been well controlled 
with 150 mg of  diazoxide daily. 
Two other  patients with solitary adenoma de- 
serve special comment.  One, a 60-year-old male, 
had a 10-g adenoma removed from the pancreatic 
tail. There  was microadenomatosis in the pancreas 
surrounding the lesion but it is thought to be of  no 
functional significance since the patient has re- 
quired no treatment for 9 years since surgery. 
Plasma glucose, plasma insulin, and insulin/glucose 
ratios are normal during repeated 72-hour fasts. 
The other  solitary adenoma of special interest 
was in a patient with MEN I. Her  plasma glucose 
and insulin levels and insulin/glucose ratios are nor- 
mal since removal of her solitary adenoma 10 years 
ago. 
Adenornatosis 
Eleven (14%) of  77 patients had adenomatosis (Ta- 
ble 1). In 4 patients the diagnosis was made intra- 
operatively by the recognition of multiple macroad- 
enomas and confirmed by frozen section micros- 
copy. In one additional patient the diagnosis was 
made by the endocrinologist in the operating room 
while sectioning an 80% distally resected pancre- 
atic segment (Table 2). He saw multiple small ad- 
enomas,  and microscopic adenomatosis was con- 
firmed by frozen section. Hyperinsulinism had per- 
sisted following our initial operation with removal 
of a 2.5-cm diameter  adenoma thought to be a soli- 
tary adenoma in the neck of the pancreas. Eighty 
Table 2. Successful intraoperative identification at first 
exploration. 
Adenomatosis 5/11 
Ne sidioblastosis 0/4 
Hyperplasia 0/2 
Table 3. Endogenous hyperinsulinism: Multiple endo- 
crine neoplasia I [6/77 patients (8%)]. 
Solitary adenoma 
Double adenoma 
Adenoma plus microadenomatosis 
Adenoma plus hyperplasia 
Multicentric beta cell carcinoma 
percent pancreatectomy has resulted in an accept- 
able but by no means ideal course in that 100 mg 
diazoxide is required twice daily and fasting plasma 
glucose levels 10 years postoperat ively are often 
around 50 mg/100 ml. 
In a 20-year-old female, a 1.0-cm diameter ad- 
enoma was removed from the pancreatic head in 
the belief that this was the patient 's  only lesion. 
Since surgery, she has been able to control symp- 
toms of hypoglycemia on diet alone, but abnormal 
plasma insulin/glucose ratios persist in excess of 
0.3 [1]. During the first tr imester of a recent preg- 
nancy, occasional overnight fasting plasma glucose 
levels were between 40 and 50 mg/100 ml. As the 
pregnancy progressed, a typical fasting plasma glu- 
cose of 94 mg/100 ml and concomitant  insulin level 
of 75 jxU/ml gave an insulin/glucose ratio of 0.8. 
Hypoglycemia in the 40 mg/100 ml range at deliv- 
ery has subsided and the patient remains well con- 
trolled on diet alone. The diagnosis of adenoma- 
tosis is presumptive in this patient and she is the 
only one in whom there is no microscopic confir- 
mation. 
There have been other lesions in the remaining 5 
patients with sporadically occurring adenomatosis.  
One patient had a macroscopic adenoma plus mi- 
croadenomatosis and 4 had visible adenomas plus 
hyperplasia. 
Patients with adenomatosis have received 
75-85% distal pancreatec tomy and vary from re- 
quiring no treatment postoperat ively to requiring as 
much as 200 mg diazoxide daily to prevent  symp- 
tomatic hypoglycemia.  
Four  of the 11 adenomatosis patients are from 3 
MEN I kindreds and had differing lesions associ- 
ated with their adenomatosis (Tables 1 and 3). In 
two, 2 macroadenomas were present,  in another a 
single macroadenoma co-existed with microad- 
enomatosis,  and in another  multiple adenomas co- 
existed with islet cell hyperplasia. These patients 
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have all responded adequately to 75-85% pancre- 
a tectomy.  
Nesidioblas tosis 
In our 4 patients with nesidioblastosis, there was 
no evidence of MEN I (Tables 1 and 3). Distal 
75-85% pancreatectomy was done but in none did 
frozen section microscopy identify the lesion (Ta- 
ble 2). Three of these patients have been reported 
before [2]. Two patients were cared for before the 
availability of  transhepatic portal venous sampling. 
One was an 1 l-year-old girl with a 2-year history of 
hypoglycemia for whom an 80% blind distal pan- 
crea tec tomy was done. While she leads an active 
life as a college student, medical control of her 
hyperinsulinism with diazoxide is not ideal be- 
cause of  erratic fasting plasma glucose levels often 
below 50 mg/100 ml. A 47-year-old man was cured 
by a 70-80% distal pancreatectomy.  Plasma glu- 
cose, plasma insulin, and insulin-to-glucose ratios 
are normal during a 72-hour fast 6 years postopera- 
tively. 
In a 66-year-old male, results of portal venous 
sampling done preoperatively were compatible 
with, but not necessarily diagnostic of, a solitary 
adenoma in the pancreatic head (Fig. 1). In spite of 
vigorous exploration of the pancreatic head, an ad- 
enoma was not found. Eighty percent  blind distal 
pancreatec tomy was done after a negative frozen 
section of the pancreatic tail. On permanent  sec- 
tion microscopy there was well-defined nesidioblas- 
tosis throughout  the resected specimen along with 
a few normal islets. The granules of the nesidi- 
oblastosis cells when stained with a specific im- 
muno-peroxidase technique were positive for insu- 
lin. A small adenoma in the resected pancreas con- 
tains glucagon on immuno-peroxidase stains but no 
insulin. Postoperatively on diazoxide, 150 mg 3 
times daily, the patient is improved, but his course 
is not optimal in that fasting glucose levels are often 
around 50 mg/100 ml. He manages his diet with 3 
daily feedings and feels no need to eat at night. Re- 
cently, a random postprandial plasma glucose of 
138 mg/100 ml was associated with a plasma insu- 
lin of 6 ~xU/ml. 
In one 20-year-old patient with nesidioblastosis, 
preoperat ive transhepatic portal venous sampling 
suggested multifocal islet cell disease. Frozen sec- 
tion microscopy was negative for nesidioblastosis 
but this lesion was subsequently demonstrated with 
immuno-peroxidase technique. 
Islet Cell Hyperplasia 
We have seen 2 patients with islet cell hyperplasia 
(Table l). A 53-year-old female before referral to us 
x , ' "  " 
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Fig. 1. Plasma insulin values in txU/100 ml during trans- 
hepatic venous catheterization (THVC) in a patient with 
proven nesidioblastosis. The preoperative interpretation 
of a solitary adenoma in the pancreatic head may not be 
correct. An adenoma could not be found. Concomitant 
systemic insulin levels are not available for comparison 
with those obtained during THVC. Mean insulin concen- 
tration of values obtained from the splenic vein, superior 
mesenteric vein, confluence and portal veins is 76 (65-86) 
p~U/ml. Venous blood draining the head of the pancreas 
had concentrations of 108,910, and 102 ~xU/ml in 3 sepa- 
rate locations suggesting multifocal hyperinsulinism. 
Five weeks before this study, systemic venous fasting 
plasma insulins were 57 and 79. 
had an 80% blind distal pancreatectomy,  and islet 
cell hyperplasia was recognized on permanent  sec- 
tion microscopy.  Her  hyperinsulinism has been 
controlled on 200-250 mg diazoxide daily for 8 
years. 
The second patient with hyperplasia was in her 
thirties when treated by 70% pancreatic resection 
over  20 years ago. She has been asymptomatic  and 
remains euglycemic. 
In both patients with hyperplasia,  f rozen section 
microscopy did not show diffuse islet cell disease. 
Multiple Endocrine Neoplasia, Type I 
There are 6 patients from 3 kindreds with M E N  I 
(Table 3). One patient had a solitary adenoma.  An- 
other patient with multicentric islet cell carcinoma 
had en-bloc distal hemipancreatec tomy including 
involved lymph nodes and a focus of  tumor toward 
the tail of  the pancreas.  An additional tumor was 
removed from the pancreatic head. Fifteen years 
since his surgery, he continues to do well with no 
hypoglycemic attacks and normal fasting insulin/ 
glucose ratios. 
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Table 4. Prevalence of diffuse islet cell disease. 
U ofM a MSHMC b Total 
All patients 13/69 4/8 17/77 (22%) 
Adenomatosis 9 2 11 
Nesidioblastosis 3 1 4 
Hyperplasia 1 1 2 
~University of Michigan Medical Center. 
bMilton S. Hershey Medical Center, Pennsylvania 
State University College of Medicine. 
Discuss ion 
In this combined series from 2 medical centers, 17 
(22%) of 77 patients with endogenous hyperinsu- 
linism had multifocal islet cell disease (Table 4). 
Multifocal islet cell disease defies easy or exact 
pathologic classification for a number of reasons. 
Some patients may have more than one beta islet 
cell abnormality and when confronted with this, we 
have classified the case according to the lesion that 
is most easily apparent. Some authors believe that 
the various beta cell diseases described have a 
common origin and that morphologic separation of 
distinct pathological entities ignores this fact. Gab- 
bay has postulated that adenomas, focal hyper- 
plastic adenomatosis, islet cell hyperplasia, islet 
hypertrophy, and nesidioblastosis may all be an 
expression of one and the same basic defect and 
had proposed the term islet cell dysmaturation syn- 
drome [3]. Jaffe et al. defined and described vari- 
ous beta cell pathological entities found in hyper- 
insulinemic hypoglycemia of infancy [4]. 
From a practical standpoint, preoperative iden- 
tification of multifocal islet cell disease in the pa- 
tient with hyperinsulinism is of great help in plan- 
ning operative intervention. The recent develop- 
ment of percutaneous transhepatic portal venous 
sampling permits differentiation of localized from 
multifocal hyperinsulinism [2, 5, 6]. More experi- 
ence with this technique is required before its true 
role and accuracy is clear. Certain circumstances 
make interpretation of transhepatic portal venous 
sampling difficult. Nesidioblastosis may be diffuse 
or focal. Thus greater focal elevations of insulin 
concentration may occur in some tributaries of the 
portal venous system than in others. Hypersecre- 
tion of insulin is not constant and intermittent fluc- 
tuation in insulin levels occurs in patients with lo- 
calized or diffuse islet cell hyperfunction. Thus it is 
essential to have concomitant systemic arterial or 
venous blood samples drawn at the time of portal 
venous samplings [6]. We would, for example, be 
better able to interpret the portal venous catheteri- 
zation values shown in Fig. 1 if simultaneous sys- 
temic insulin levels were available. For these rea- 
sons, results of transhepatic venous catheteriza- 
tion may give the appearance of indicating local- 
ized disease (adenoma) when diffuse disease is 
present. Also, the high prevalence of multifocal or 
diffuse islet cell disease in patients with hyperin- 
sulinism who have MEN I or who are members of 
such kindreds should lead one to assume preopera- 
tively that more than one focal lesion is present. 
In Frantz's original description of beta cell ad- 
enomatosis in 1944, hypoglycemia persisted if only 
visible or palpable adenomas were removed [7]. 
Nesidioblastosis, the original multifocal islet cell 
disorder to be recognized, was first suggested by 
Laidlaw in 1938 [8]. In many patients with nesidi- 
oblastosis, limited pancreatic resection has proven 
inadequate on prolonged follow-up. In a patient 
who has a negative exploration for solitary ad- 
enoma, intraoperative real-time ultrasonography 
may be helpful. LeQuesne is prominent among ad- 
vocates of primary resection of the pancreatic head 
if no insulin-secreting disease condition is found in 
hyperinsulinism [9]. We disagree because of the 
high likelihood of multifocal islet cell disease when 
there is no discernible pancreatic islet cell disease 
at operation. We prefer a 75-85% distal pancreatec- 
tomy as a more restrained alternative associated 
with an appreciably lower mortality rate. We have 
described previously our diagnostic criteria and op- 
erative treatment of endogenous hyperinsulinism 
[10]. The single operative death in our series was 
from a coagulopathy 1 month after removal of a sin- 
gle adenoma in a 64-year-old male. He was the old- 
est patient on whom we have operated. 
The variety of multifocal islet cell pathological 
conditions is well exemplified in our patients with 
and without MEN I. Other islet cell endocrinologic 
abnormalities may co-exist with hyperinsulinism in 
patients with MEN I and this is the subject of a 
separate report [11]. Conceivably other forms of 
islet cell hyperplasia may co-exist with endogen- 
ous hyperinsulinism from a solitary beta cell ad- 
enoma. This could lead to unnecessary 80% pan- 
creatic dissection when only adenoma excision is 
needed to control hyperinsulinism. Intraoperative 
immunocytochemistry is a possible solution to this 
problem but we have no experience with it. 
For the majority of patients with hyperinsulin- 
ism due to multifocal islet cell disease, there is no 
cure of hyperinsulinism from 70-80% pancreatic re- 
section. Frequently, hyperinsulinism will persist af- 
ter subtotal pancreatic resection for functioning, 
multifocal islet cell disease. However, the patients 
do become more manageable on drug regimens 
which typically were ineffective before pancreatic 
resection. Surgery for endogenous hyperinsulinism 
continues to require thoughtful collaboration be- 
tween endocrinologists, radiologists, pathologists, 
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and surgeons and must  be highly individualized to 
pathological  and functional subtleties of  each pa- 
tient. 
R6sum6 
Chez 77 malades,  provenant  de 2 centres 
m6dicaux, qui pr6sentaient un hyperinsulinisme 
endog6ne, 17 cas de 16sions diffuses des ilots de 
Langerhans  ont 6t6 d6nombr6s.  Ce fait est donc 
loin d '6tre  exceptionnel  et cette 6rude a pour  but de 
le souligner. 
Parmi ces 17 malades,  11 pr6sentaient des 
ad6nomes multiples (ad6nomatoses) ,  4 des 
n6sidoblastomes (anomalies tissulaires multifo- 
cales), 2 des hyperplasies  cellulaires insulaires. 
Chez ces 77 malades,  6 cas de M E N  type I furent 
individualis6s, 4 d 'en t re  eux pr6sentaient  une 
maladie insulaire diffuse. 
Les  auteurs,  forts de cette exp6riences insistent 
sur les principes du trai tement de ce type 
d 'affection.  Ils insistent sur le fait que l '6tude his- 
tologique ex temporan6e  ne permet  pas d'identifier 
les n6sidoblastomes et les hyperplasies cellulaires 
insulaires et que dans 70%-80% des cas les 
r6sections pancr6atiques ne permet tent  pas 
d 'ob ten i r  la gu6rison. 
Resumen 
Un problema constante para  el cirujano que opera  
pacientes con hiperinsulinismo end6geno es el de 
qu6 hacer  cuando no se encuentre patologia en el 
curso de la operaci6n una vez realizada la 
exploraci6n preliminar del pfincreas. Los  ade- 
nomas  solitarios de c61ulas beta pueden pasar  des- 
apercibidos cuando no son palpables;  la 
identificaci6n de la enfermedad difusa de las c61ulas 
insulares plantea muchos problemas.  Reconoce-  
mos tres al teraciones principales de tipo difuso: ade- 
nomatosis  de c61ulas beta,  nesidioblastosis e 
hiperplasia pancrefitica de c61ulas beta. Ademfis, 
multiples macroadenomas  pueden coexistir o no 
con microadenomatos is  o con hiperplasia en cier- 
tos pacientes  con hiperinsulinismo. Los des6rdenes 
de c~lulas insulares de tipo multifocal son particu- 
larmente frecuentes  en pacientes con Neoplas ia  
Endocr ina  Mt~ltiple Tipo I. 
Entre  77 pacientes con hiperinsulinismo 
end6geno observados  en dos centros m6dicos, la 
enfermedad de c61ulas insulares de tipo difuso es- 
tuvo presente en 17 pacientes  (22%). Teniendo en 
cuenta  que la enfermedad de c61ulas insulares de 
tipo difuso plantea problemas  especiales en cuanto 
a su manejo,  este informe hace 6nfasis en lo rela- 
tivo a su prevalencia.  
En el grupo de pacientes  con enfermedad de 
c61ulas insulares de tipo difuso se encont raron  11 
pacientes con adenomatos is ,  cuatro con nesidio- 
blastosis y dos con hiperplasia de c61ulas insu- 
lates. Seis de los 77 pacientes  fueron hallados en 
familiares con Neoplas ia  Endocr ina  Mt~ltiple Tipo 
I; la enfermedad difusa de c61ulas insulares fue do- 
cumentada  en cuatro.  
Se presentan los principios de manejo en pa- 
cientes con enfermedad de c61ulas insulares de tipo 
difuso. La  miscroscopfa  de cortes por  congelaci6n 
fall6 en la identificaci6n de la nesidioblastosis o la 
hiperplasia de c61ulas insulares. 
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